CCO Oncology Podcast

Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

Episode Summary

In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, discuss new data for gynecologic cancers presented at the virtual ASCO 2021 annual meeting, including novel data for single-agent immunotherapy in patients with endometrial cancer, data for novel agents targeting the folate receptor-α in ovarian cancer, and data for a novel bifunctional fusion proteins cotargeting the TGF-β receptor and PD-L1 pathways in cervical cancers.

Episode Notes

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:

• Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancer
• Updated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)
• Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancer
• Results from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancer
• Highly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancer
• A post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1
• Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancers

Presenters:

David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas  

Melissa M. Hardesty, MD, MPH
Affiliate Associate Professor
OB/GYN/GYN Oncology
University of Alaska Anchorage
Gynecologic Oncologist and Managing Partner
Alaska Women’s Cancer Care
Anchorage, Alaska

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3dAttwi